Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 July 2022 | Story Dr Nitha Ramnath | Photo Supplied
Leah Molatseli.


Leah Molatseli– alumna and Council member of the University of the Free State (UFS) – is the first African woman to be recognised by the American Bar Association in its list of Women of Legal Tech for her contribution and influence in the legal tech industry. A commitment to diversity is one of the core values of the American Bar Association, which the Law Practice Division aims to reinforce in the legal tech sector. Annually, talented women in the legal tech space are recognised for making an impact on legal tech.

A lawyer by profession, published legal tech author and speaker, as well as legal tech and innovation specialist, Molatseli uses technology and innovative means to empower and educate law professionals.  She is currently head of business development at Legal Interact, a South African law firm that provides technology solutions for the legal industry. 

Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, congratulated Molatseli on her achievement. “On behalf of the executive committee of the University of the Free State (UFS) and the university community, I would like to extend my warmest congratulations on being recognised by the American Bar Association for your contribution to the legal tech industry. Being the first African woman to be honoured in this way makes this accomplishment even more extraordinary. You are a trailblazer in your field in so many ways,” said Prof Petersen. 

Prof Petersen said, “The university, and the Faculty of Law in particular, is proud to be associated with you. We also appreciate your continued support to the institution. Your dedication and expertise inspire us all – I will continue to follow your professional journey, because I know there is much more in store”. Prof Petersen continued to thank Molatseli for contributing to the legal field in an innovative and contemporary manner. 

Molatseli is host of and guest speaker for various legal tech talks globally, as well as a guest lecturer at the University of Cape Town, where she develops and teaches legal tech innovation-related courses to the legal industry. A Mandela Washington fellow, as well as a Notre Dame alumna, she is a member of the Women in Tech South African Chapter, a country member for the Global Legal Tech Consortium, and is one of 2022’s ILTA’s Most Influential Women in Legal Tech honourees.  


News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept